X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (42901) 42901
Newspaper Article (689) 689
Newsletter (188) 188
Book Chapter (159) 159
Magazine Article (50) 50
Book / eBook (49) 49
Transcript (32) 32
Web Resource (19) 19
Dissertation (15) 15
Conference Proceeding (11) 11
Trade Publication Article (6) 6
Book Review (4) 4
Government Document (3) 3
Streaming Video (3) 3
Publication (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (29691) 29691
angiogenesis (27695) 27695
animals (16267) 16267
oncology (13242) 13242
female (12908) 12908
male (12293) 12293
angiogenesis inhibitors - therapeutic use (12039) 12039
cancer (11829) 11829
vascular endothelial growth factor (8941) 8941
mice (8830) 8830
expression (7245) 7245
endothelial growth-factor (7151) 7151
tumors (6917) 6917
middle aged (6870) 6870
metastasis (6722) 6722
bevacizumab (6653) 6653
apoptosis (6267) 6267
aged (6218) 6218
proteins (5695) 5695
research (5355) 5355
care and treatment (5244) 5244
adult (4638) 4638
cell line, tumor (4630) 4630
cell biology (4587) 4587
gene expression (4562) 4562
chemotherapy (4553) 4553
kinases (4489) 4489
analysis (4453) 4453
treatment outcome (4341) 4341
angiogenesis inhibitors (4131) 4131
ophthalmology (4102) 4102
health aspects (4090) 4090
vascular endothelial growth factor a - antagonists & inhibitors (4067) 4067
medicine (3946) 3946
antineoplastic agents - therapeutic use (3880) 3880
signal transduction (3719) 3719
pharmacology & pharmacy (3658) 3658
therapy (3639) 3639
vegf (3600) 3600
cancer therapies (3595) 3595
research article (3590) 3590
growth (3407) 3407
neovascularization (3380) 3380
cells (3376) 3376
angiogenesis inhibitors - pharmacology (3374) 3374
multidisciplinary sciences (3323) 3323
inflammation (3302) 3302
neovascularization, pathologic - drug therapy (3279) 3279
cell proliferation (3268) 3268
medicine, research & experimental (3171) 3171
rodents (3109) 3109
hypoxia (3098) 3098
studies (3047) 3047
biochemistry & molecular biology (2924) 2924
inhibition (2906) 2906
endothelial cells (2849) 2849
medicine & public health (2838) 2838
breast cancer (2832) 2832
rats (2817) 2817
science (2794) 2794
stem cells (2794) 2794
aged, 80 and over (2783) 2783
vascular endothelial growth factor a - metabolism (2727) 2727
angiogenesis inhibitors - administration & dosage (2681) 2681
physiological aspects (2680) 2680
development and progression (2660) 2660
neoplasms - drug therapy (2604) 2604
growth factors (2594) 2594
biology (2590) 2590
cell growth (2589) 2589
activation (2564) 2564
cell proliferation - drug effects (2549) 2549
disease models, animal (2508) 2508
endothelium (2475) 2475
tumor angiogenesis (2441) 2441
in-vivo (2396) 2396
in-vitro (2385) 2385
prognosis (2360) 2360
antibodies, monoclonal - therapeutic use (2343) 2343
mice, nude (2321) 2321
surgery (2321) 2321
antineoplastic combined chemotherapy protocols - therapeutic use (2317) 2317
metastases (2303) 2303
survival (2283) 2283
medical research (2257) 2257
medical prognosis (2254) 2254
genetic aspects (2237) 2237
cytokines (2236) 2236
antibodies, monoclonal, humanized (2235) 2235
immunohistochemistry (2220) 2220
review (2191) 2191
intravitreal injections (2146) 2146
cell adhesion & migration (2117) 2117
drug therapy (2107) 2107
clinical trials (2103) 2103
antineoplastic agents - pharmacology (2062) 2062
cells, cultured (2052) 2052
angiogenesis inhibitors - adverse effects (2019) 2019
macular degeneration (2016) 2016
antibodies, monoclonal, humanized - therapeutic use (1987) 1987
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (20) 20
Gerstein Science - Stacks (13) 13
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Missing (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (43302) 43302
French (345) 345
German (221) 221
Japanese (191) 191
Chinese (116) 116
Spanish (104) 104
Portuguese (69) 69
Polish (39) 39
Russian (36) 36
Hungarian (27) 27
Czech (21) 21
Italian (20) 20
Dutch (18) 18
Romanian (18) 18
Danish (12) 12
Norwegian (12) 12
Finnish (9) 9
Korean (8) 8
Hebrew (7) 7
Swedish (6) 6
Turkish (6) 6
Croatian (3) 3
Icelandic (2) 2
Slovak (2) 2
Lithuanian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti‐vascular endothelial growth factor... 
Endocrine & metabolic | Receptors, Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor A | Macular oedema | Laser Coagulation | Visual Acuity | Retinal disease | Angiogenesis Inhibitors | Recombinant Fusion Proteins | Bevacizumab | Randomized Controlled Trials as Topic | Diabetic eye disease | Aptamers, Nucleotide | Ranibizumab | Quality of Life | Macular Edema | Diabetes | Eyes & vision | Network Meta‐Analysis | Triamcinolone | Medicine General & Introductory Medical Sciences | Diabetic Retinopathy | Retinal disease (including age‐related macular degeneration) | CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10043, pp. 518 - 529
...) pathway inhibitors into the therapeutic armoury. Although some tumours such as renal cell carcinoma, ovarian and cervical cancers, and pancreatic neuroendocrine... 
Internal Medicine | PHASE-III TRIAL | ADVANCED HEPATOCELLULAR-CARCINOMA | BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | PANCREATIC NEUROENDOCRINE TUMORS | TYROSINE KINASE INHIBITOR | RECURRENT OVARIAN-CANCER | ANTI-ANGIOGENIC THERAPY | RESISTANT PROSTATE-CANCER | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Humans | Drug Resistance, Neoplasm | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Angiogenesis Inhibitors - therapeutic use | Biomarkers, Tumor - metabolism | Female | Neovascularization, Pathologic - prevention & control | Molecular Targeted Therapy - methods | Receptor, TIE-2 - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Neoplasms - blood supply | Piperazines - therapeutic use | Angiopoietin-1 - antagonists & inhibitors | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Neoplasms - drug therapy | Biomarkers, Tumor - blood | Disease-Free Survival | Phthalazines - therapeutic use | Signal Transduction - drug effects | Neovascularization, Pathologic - drug therapy | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinolines - therapeutic use | Antimitotic agents | Pancreatic cancer | Melanoma | Neovascularization | Antineoplastic agents | Vascular endothelial growth factor | Prostate cancer | Cervical cancer | Drugs | Angiogenesis | Chemotherapy | Clinical trials | Oncology | Metastasis | Cancer therapies | Tumors | Cancer
Journal Article
International journal of molecular sciences, ISSN 1661-6596, 10/2017, Volume 18, Issue 10, p. 2021
...). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy... 
Nintedanib | Angiogenesis | Ramucirumab | VEGF trap | Vascular endothelial growth factor (VEGF) | Bevacizumab | ramucirumab | PLACEBO-CONTROLLED-TRIAL | MAINTENANCE BEVACIZUMAB | angiogenesis | BIOCHEMISTRY & MOLECULAR BIOLOGY | vascular endothelial growth factor (VEGF) | OPEN-LABEL | COMBINATION | CHEMISTRY, MULTIDISCIPLINARY | CELL LUNG-CANCER | PHASE-III TRIAL | bevacizumab | DOUBLE-BLIND | nintedanib | 1ST-LINE THERAPY | PLUS ERLOTINIB | ENDOTHELIAL GROWTH-FACTOR | Neovascularization, Pathologic - mortality | Niacinamide - analogs & derivatives | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Bevacizumab - therapeutic use | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Neovascularization, Pathologic - pathology | Taxoids - therapeutic use | Clinical Trials, Phase III as Topic | Adenocarcinoma - metabolism | Angiogenesis Inhibitors - therapeutic use | Pyrroles - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - metabolism | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Piperidines - therapeutic use | Quinazolines - therapeutic use | Indoles - therapeutic use | Neovascularization, Pathologic - metabolism | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Adenocarcinoma | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Histology | Metastasis | Patients | Survival | Two phase | Biological activity | Metastases | Chemotherapy | Antiangiogenics | Antiangiogenic agents | Biomarkers | Angiogenesis inhibitors | Tumors
Journal Article
Cellular and molecular life sciences : CMLS, ISSN 1420-9071, 2008, Volume 66, Issue 7, pp. 1163 - 1177
Journal Article
Cochrane database of systematic reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
DA VINCI | Macular Edema [drug therapy surgery] | Growth Factor [therapeutic use] | Humans | RANIBIZUMAB PLUS PROMPT | Receptors, Vascular Endothelial | RANDOMIZED CONTROLLED-TRIAL | Bevacizumab | DEFERRED LASER | Antibodies, Monoclonal, Humanized [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Recombinant Fusion Proteins [therapeutic use] | PEGAPTANIB SODIUM | Angiogenesis Inhibitors [therapeutic use] | Laser Coagulation [methods] | Ranibizumab | QUALITY-OF-LIFE | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | COST-EFFECTIVENESS | Triamcinolone [therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Antibodies, Monoclonal [therapeutic use] | Aptamers, Nucleotide [therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Network Meta-Analysis | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Quality of Life
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4782, 2009, Volume 6, Issue 8, pp. 465 - 477
.... Although most adverse effects of VEGF inhibitors are modest and manageable, some are associated with serious and life-threatening consequences, particularly in high-risk patients and in certain clinical settings... 
ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | TYROSINE KINASE INHIBITOR | PHASE-II | OVARIAN-CANCER | PACLITAXEL PLUS BEVACIZUMAB | THROMBOTIC MICROANGIOPATHY | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | COOPERATIVE-ONCOLOGY-GROUP | Humans | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Benzenesulfonates - adverse effects | Bevacizumab | Brain Diseases - chemically induced | Benzenesulfonates - pharmacology | Pyridines - adverse effects | Drug Interactions | Kidney Diseases - chemically induced | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | Antibodies, Monoclonal - pharmacology | Risk Factors | Angiogenesis Inhibitors - pharmacology | Forecasting | Indoles - adverse effects | Indoles - therapeutic use | Cardiovascular Diseases - chemically induced | Hemorrhage - chemically induced | Vascular Endothelial Growth Factor A - physiology | Niacinamide - analogs & derivatives | Receptors, Vascular Endothelial Growth Factor - physiology | Clinical Trials as Topic - statistics & numerical data | Neoplasm Proteins - physiology | Antibodies, Monoclonal - adverse effects | Cardiovascular Diseases - therapy | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Drug Delivery Systems | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Pyrroles - therapeutic use | Wound Healing - drug effects | Pyridines - therapeutic use | Hemorrhage - therapy | Pyrroles - pharmacology | Protein Kinase Inhibitors - therapeutic use | Capillary Leak Syndrome - chemically induced | Kidney Diseases - therapy | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Gastrointestinal Diseases - chemically induced | Antimitotic agents | Complications and side effects | Care and treatment | Colorectal cancer | Physiological aspects | Development and progression | Poisoning | Antineoplastic agents | Vascular endothelial growth factor | Risk factors | Tumors | Cancer | Index Medicus
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 2017, Volume 18, Issue 7, p. 1414
...) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response... 
Histone deacetylase inhibitors | Anti-angiogenic effect | Cell cycle arrest | Drug combinations | Histone deacetylases | Autophagy | Apoptosis | Cancer | HDAC INHIBITORS | autophagy | SUBEROYLANILIDE HYDROXAMIC ACID | HUMAN LEUKEMIA-CELLS | NITRIC-OXIDE SYNTHASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | TUMOR-SUPPRESSOR GENES | apoptosis | VALPROIC ACID | cell cycle arrest | anti-angiogenic effect | CHEMISTRY, MULTIDISCIPLINARY | drug combinations | CELL LUNG-CANCER | EPITHELIAL-MESENCHYMAL TRANSITION | PHASE-II TRIAL | LONG NONCODING RNA | histone deacetylases | cancer | histone deacetylase inhibitors | Immunomodulation - drug effects | Apoptosis - drug effects | Humans | Angiogenesis Inhibitors - pharmacology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Autophagy - drug effects | Acetylation - drug effects | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Cycle Checkpoints - drug effects | Angiogenesis Inhibitors - therapeutic use | Histone Deacetylase Inhibitors - pharmacology | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Gene Expression Regulation, Neoplastic - drug effects | Drug Evaluation, Preclinical
Journal Article